Pharmacogenomics (PGx) Community

The Pharmacogenomics Community combines the disciplines of biochemistry, biophysics, genetics, molecular biology, bioinformatics, and pharmacology to elucidate the mechanisms of drug action, toxicity, metabolism and transport and to identify genetic determinants of variability in drug exposure, response and toxicity.

Community Goals

  • Facilitate interaction and collaboration between members of the Pharmacogenomics Community via social media and networking opportunities
  • Spur interest and growth in the area of pharmacogenomics
  • Act as the primary home for researchers in the area of pharmacogenomics
  • Support member engagement in the Precision Medicine Initiative

Join the LinkedIn Group.

University of Florida Training Program
The University of Florida announces a new training program funded by the National Institutes of Health’s National Human Genomic Research Institute. The Program for Applied Research and Development in Genomic Medicine, or PARADIGM, offers trainees mentoring from world-renowned scientists, clinical exposure in multiple areas of genomic medicine and stimulating career development opportunities within the robust, interdisciplinary research environment at UF. Learn more here.

Are you interested in volunteering within the PMG Community? Email your interest to Jason Karnes, PharmD, PhD, or update your involvement interests online.

Upcoming Webinars
ASCPT Members-Only Webinar Presented by the Pharmacogenomics Community (PGx)
Title: Functional annotation of variants of uncertain significance
Date and Time: 2:00 PM EST, Monday, December 10, 2018 
Speakers: Dr. Kiran Musunuru
Moderator: Dr. Sonal Singh
Description: The presentation will describe an approach based on induced pluripotent stem cells (iPSCs) to functionally annotate variants of uncertain significance in cardiomyopathy-associated genes. The platform makes use of CRISPR-Cas9 and other gene-editing tools to rapidly insert or correct patients’ variants in iPSCs, followed by differentiation of the iPSCs into cardiomyocytes in a dish. Various properties of these cardiomyocytes—such as morphological and electrophysiological characteristics—can provide insight into whether the variants are benign or pathogenic. The approach has been used for annotation of patients’ variants in TNNT2 and LMNA and has been developed to the point that it can be used to inform patient management in real time. A specific example regarding a 65-year-old woman with hypertrophic cardiomyopathy and a variant of uncertain significance in TNNT2, which was successfully annotated between her first and second clinic visits and had implications for cascade genetic testing of her children and grandchildren, will be highlighted.
Registration: https://attendee.gotowebinar.com/register/5191457794941374978

Past Webinars


Jason H. Karnes, PharmD, PhD, BCPS

Community Chair


Laura Ramsey, PhD

Community Vice Chair


Yui Wing Francis Lam, PharmD

Community Past Chair


PGx Community Programming Steering Committee
Dan Hertz, PharmD, PhD - Chair
Meghan Arwood, PharmD
Sharvari Bhagwat, PhD
J. Kevin Hicks, PharmD, PhD
Ming-Fen Ho, PhD
Jesse Swen, PharmD, PhD

PGx Community Membership Outreach Steering Committee
Sonal Singh, PhD - Co-Chair
D. Max Smith, PharmD - Co-Chair
Josiah Allen
Otito Iwuchukwu, PhD
Jia Yu, PhD
Photo Gallery
Recent News
  • A Unique Collection of State-of-the-Art Pharmacometric and Systems Pharmacology Approaches in Rare Diseases Pharmacology and Therapeutics
    November 16, 2018
  • New Board Members Appointed
    November 15, 2018
  • ASCPT Members-Only Webinar Presented by the Pharmacogenomics Community (PGx)
    November 14, 2018
Contact Us